Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of Ibrutinib Doses in CLL
NCT02801578Phase 3Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2016
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ibrutinib in chronic lymphocytic leukemia (CLL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Participants With >/= 95 % Bruton's Tyrosine Kinase (BTK) Occupancy up to 90 days. Started Jul 2016; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02801578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02801578.